Treatment of ascites and solid tumors in mice (Sarcoma-I and Ehrlich ascites carcinoma) with bovine enterovirus-I resulted in regression of the tumors without any pathological effect on the animals. Death of mice with lymphatic-leukemia L4946 was delayed after such treatment. The oncolytic specificity of the virus does not appear to involve the production of interferon, but requires specific adsorption of virus to the tumor cells. The specificity of killing extends to cells in culture, since viral-transformed cells and oncogenic cells are susceptible to the virus, in contrast to cells of untransformed lines and cells of primary cultures, which are resistant.
The use of viruses specific for the destruction of cancer has remained essentially a laboratory curiosity. Many researchers have suggested that it should be possible to utilize biological mechanisms with sufficient specificity to discriminate between a malignant tumor cell and a normal cell in order to control tumor growth. During the last forty years, a few laboratories have investigated this possibility with different viruses (1) (2) (3) . However, apart from a report (4) of the partial inhibition of a transplantable murine leukemia by M-P virus, most oncolytic viruses have been found to be too lethal for the host for this treatment to be practical.
A few successful instances of oncolysis in man have been reported. However, the results of such experiments are difficult to evaluate since viral treatment followed other therapeutic measures that could have played a part in tumor regression. Wheelock and Dingle (5) achieved a temporary remission of acute leukemia in a human subject by successive inoculation of six different viruses.
In this paper, we present evidence of viral oncolysis in rodents carrying both solid and ascites tumors without any apparent effect on the host animal.
MATERIALS AND METHODS Virus production
Bovine enterovirus-1 (BEV-1) was grown in cell monolayers of Maden Bovine kidney or mouse L-cells in Eagle's minimal essential medium supplemented with 5% chick serum, streptomycin (100 Mg/ml), penicillin (100 units/ml), and fungizone (2.5 ,zg/ml). High-titer lysates of BEV-1 were produced by infecting monolayers of confluent roller cultures (690 cm2; about 5 X 108 cells) with virus at a multiplicity of infection of 1-10 plaque-forming units (PFU)/cell in medium without serum. Cultures were rolled for 1 hr at 1 rpm on a Bellco roller apparatus to allow virus adsorption. At that time, fresh medium containing 5% serum was added, and infected cells were incubated 12-15 hr. Bottles were passed through three cycles of freeze and thaw to release virus. The cell debris was removed by centrifugation for 10 min at 3000 rpm. Lysates were stored in small aliquots at -20°C. BEV-1 was assayed by the plaque technique and hemagglutination as previously described (6) .
Tumors
Ehrlich ascites tumor and Sarcoma-1 (SA-1), in ascites form, were maintained in the peritoneal cavity of adult SwissWebster mice. The tumor cells were transferred intraperitoneally at 8-day intervals. Tumor growth was measured by direct cell count in a hemocytometer, or by measuring the increase in weight of the mouse, which is a reflection of proliferation of tumor cells and increased ascites fluid (3) The histological materials were fixed in 5% formaldehyde for a minimum of [8] [9] [10] hr, then processed through alcohol and embedded in paraffin. They were cut at 6 ,um and stained with hematoxvlin and eosin. The smears were air-dried and fixed and stained with Wright's stain.
RESULTS
We have previously reported that Ehrlich ascites tumor and Sarcoma-1 grown in the peritoneal cavity of adult mice regressed rapidly after treatment with BEV-1 (6) . No tumor cells were detectable by microscopic examination in such mice 48 hr after treatment. In control animals (no tumors, treated with BEV-1) no adverse effect on the animals was noted; such animals appear to be healthy, with sleek fur and normal weight gain. "Cured" mice have been retained as long as 1 year without recurrence of the tumor. In order to examine the effect of time of inoculation with BEV-1 after SA-1 injection, 105 SA-1 cells were transplanted into 35 adult mice. At the same time, and on the next 4 consecutive days, 108 BEV-1 were injected into the site of the tumor in different groups of animals. 12 days after tumor transplantation, the size of the tumor was measured. All of the control animals (10) It was of interest to examine whether tumor regression was due to the direct cytolytic effect of the virus, or to an indirect effect in which the presence of viral protein or RNA was sufficient. It has been suggested that oncolysis may be due to interferon production in the tumor cells (5) . Many animal cancers have been shown to have a viral etiology, so that infection of the tumor cell by a second virus (BEV-1) could lead to interferon production. This interferon would then act to interfere with the growth of the tumor cell. Since foreign nucleic acid is sufficient to induce interferon synthesis, ultraviolet-irradiated virus is able to induce synthesis of interferon (7) . Since inactivated virus is incapable of replication, we could determine whether tumor regression is due to direct cytolysis (as a result of viral replication) or is a consequence of interferon stimulation.
A BEV-1 viral lysate was treated with UV radiation to 100% lethality, as measured by plaque assay. When inactivated virus was injected intraperitoneally into mice carrying Ehrlich ascites tumor or Sarcoma-1 in the peritoneal cavity, no regression of the tumor occurred. These animals showed a weight increase (reflecting tumor growth), as did the untreated controls (Fig. 1) . However, active virus from the same lysate gave a typical oncolytic pattern, i.e., rapid decrease in weight, suggesting direct cytolysis as the mechanism of tumor regression.
In a further test of this mechanism of tumor regression, tumors of animals treated with virus were studied histologically. The results of this investigation show that there are almost no tumor cells present in the peritoneal cavity of treated animals, and that the few remaining tumor cells are undergoing cytolysis. In the treated solid tumor, there is less necrosis of muscle tissue than in controls, and the tumor appears to be undergoing degenerative changes. Groups of cells appear to be surrounded by polymorphonuclear leukocytes, a phenomenon absent in untreated animals [ Fig. 2 (a-d) ] .
The specificity of the virus for the tumor cell could be due to either an external or internal barrier to viral infection of the normal host cell. Reasons (8) have shown that the kinetics of viral adsorption are the same for intact cells and for cellular debris resulting from freeze-thaw cycles. Mouse kidneys (organs) and Ehrlich ascites cells were either homogenized with a Dounce homogenizer or passed through cycles of freeze-thaw. The cellular debris was centrifuged, and the pelleted material was resuspended and tested for its ability to adsorb BEV-1. As is shown in Fig. 2 , BEV-1 did not adsorb to the kidney homogenate, although there was efficient adsorption of this preparation to an Ehrlich ascites tumor homogenate. To exclude the possibility that all viral receptor sites on the kidney have been damaged, mengovirus adsorption to both homogenized tissues was measured. This occurred as expected.
The specificity of BEV-1 infection was further tested by examining whether any correlation could be found between the cytopathic effect of BEV-1 on cells in culture and known oncogenic cell lines. Table 3 lists the cell lines tested. No such effect was noted on mouse cell line 3T3 (nononcogenic), although two polyoma-transformed cell lines were sensitive to the virus. Note that three human oncogenic cell lines, HeLa, KB, and Hep-2, are very sensitive to virus infection. Adsorption was also tested and, in the cases where no cytopathic effect was observed, the virus was found incapable of irreversible attachment. In those cell lines exhibiting cytopathic effect, adsorption (determined by titering the inoculating supernatant after the 1-hr adsorption period) was 90-95% complete.
DISCUSSION
This paper presents evidence that a virus that is not virulent for a specific host can be used therapeutically to treat either an ascites tumor or a solid tumor. In this particular case, we have used BEV-1, a bovine enterovirus apparently harmless to rodents. In culture, the virus forms large plaques on bovine kidney and L-cell monolayers within 48 hr; its eclipse time is short, about 1-1.5 hr after infection, and it BEV-1, at a multiplicity of 20. was added to cell debris from both homogenized mouse kidney and EAT, at a concentration comparable to 2 X 106 cells/ml. Samples of 1 ml were removed at 30-min intervals and centrifuged at 3000 rpm for 10 min. Supernatants were assayed for unadsorbed virus; the number of unadsorbed viruses was determined by both plaque assay and hemagglutination. A control with a mouse-specific virus, mengovirus, are sensitive to BEV-1 suggests that such alterations may be a general characteristic of many tumors.
Preliminary experiments with hepatoma 3924 in rats show a partial regression of tumor growth. A possible reason for the absence of complete regression of some of the tumors might be a host-developed immunity to BEV-1. This might be overcome by utilizing antigenically different viruses. For example, four distinct serotypes of BEV-1 are known (10) . Sequential infection with each one might overcome immunity problems. Furthermore, treatment with virus might be used after surgical removal of the tumor to eradicate any remaining or metastasizing cells. Nonvirulent viruses might also be used in conjunction with immunosuppressive drugs.
It is not to be expected that all tumor cells will be sensitive to any one group of virus. The lack of killing of L4946 cells could be due to resistance of these cells to BEV-1. Other nonvirulent viruses should be screened on various tumors to examine their host specificity.
Oncolytic viruses might also play a role in diagnostic techniques. If adsorption of the virus is specific to neoplastic tissue, tagged BEV-1 (fluorescent) might be used to detect cancerous growth.
It is our hope that these observations may be extended to different human cancers and to in vivo therapeutic processes.
